Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Feb 15;4(5):487–497. doi: 10.7150/thno.8263

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.

PMC Copyright notice

In vivo evalution of CP-MSNP/siRNA tumor accumulation, biodistribution, and suppression of gene expression. (A) Intravital microscopic images captured one hour after administration of CP-MSNP/Alexa555. CP-MSNP/Alexa555 siRNA particles are shown in red, and tumor blood vessels are displayed in green (FITC-dextran). White arrows point to selected particles that have left the tumor vasculature. (B) Measurement of CP-MSNP/Alexa555 siRNA in tumor blood vessels at various time points by intravital microscopy. (C-E) Biodistribution of CP-MSNP/Alexa555 siRNA in tumor tissue and major organs. (C) Fluorescent intensity from tumor and major organs. Samples are presented as a: heart, b: liver, c: spleen, d: lung, e: kidney, and f: tumor. (D) Percentage of fluorescent intensity/sample and (E) percentage of fluorescent intensity/gram sample are presented. Percentage was calculated as fluorescent intensity in the sample/total combined intensity. (F) Western blot analysis on knockdown of PKM2 expression 5 days after treatment with CP-MSNP/siRNA (n = 3 mice/group).